Skye Bioscience inc (OTCQB:SKYE) Chief Development Officer Tu Diep joined Proactive to discuss its agreement with Novotech Health Holdings, a full-service contract research organization in Asia-Pacific the group has hired for the upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma.
It will work alongside investigators of the planned study to support aspects of the clinical trial including feasibility assessments, ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, reporting, and project and vendor management.